Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.48 |
| ▸ | HTR2C | P28335 | 11/20 | 0.48 |
| ▸ | HTR2B | P41595 | 10/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 3/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557462 | 0.92 | HTR2A (0.48) | HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL3556569 | 0.89 | HTR2C (0.40) | HTR2AHTR2CHTR2BXIAPPARP1 | |
| SCHEMBL3551438 | 0.88 | HTR2A (0.39) | HTR2AHTR2CHTR2BXIAPBIRC2 | |
| SCHEMBL3555858 | 0.88 | HTR2A (0.53) | HTR2AHTR2CHTR2BXIAPBIRC2 | |
| SCHEMBL3556629 | 0.88 | HTR2C (0.48) | HTR2AHTR2CHTR2BXIAPBIRC2 | |
| SCHEMBL3557257 | 0.88 | HTR2A (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL3554181 | 0.86 | HTR2A (0.52) | HTR2AHTR2CHTR2BBIRC2 | |
| SCHEMBL3559405 | 0.86 | HTR2A (0.50) | HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL3563490 | 0.85 | HTR2A (0.51) | HTR2AHTR2CHTR2BXIAPBIRC2 | |
| SCHEMBL3554372 | 0.82 | HTR2C (0.38) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | claimed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | claimed |
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | HTR2A 3/4885HTR2C 5/4885HTR2B 4/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HTR2A 4/4885HTR2C 6/4885HTR2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.